Marker Therapeutics, Inc. financial data

Symbol
MRKR on Nasdaq
Location
2450 Holcombe Blvd, Suite Bcm A, Ms: Bcm251, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 472 % -23.3%
Debt-to-equity 26.9 % +38.6%
Return On Equity -115 % -44.3%
Return On Assets -90.3 % -35.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.9M shares +45%
Common Stock, Shares, Outstanding 11.3M shares +27%
Entity Public Float 48.5M USD +110%
Common Stock, Value, Issued 11.3K USD +26.8%
Weighted Average Number of Shares Outstanding, Basic 14M shares +56.5%
Weighted Average Number of Shares Outstanding, Diluted 14M shares +56.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.9M USD +65.8%
General and Administrative Expense 4.2M USD -18.5%
Operating Income (Loss) -15.1M USD -37.6%
Net Income (Loss) Attributable to Parent -14.6M USD -40.9%
Earnings Per Share, Basic -1 USD/shares -15.3%
Earnings Per Share, Diluted -1 USD/shares -15.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.5M USD +34.1%
Assets, Current 14.8M USD +26.5%
Property, Plant and Equipment, Net 11.7M USD -18.5%
Operating Lease, Right-of-Use Asset 5.33M USD -44.4%
Assets 14.8M USD +26.5%
Accounts Payable, Current 1.72M USD +58.5%
Employee-related Liabilities, Current 65K USD +4.84%
Liabilities, Current 4.28M USD +117%
Operating Lease, Liability, Noncurrent 6.82M USD -38.2%
Liabilities 4.28M USD +117%
Retained Earnings (Accumulated Deficit) -455M USD -3.31%
Stockholders' Equity Attributable to Parent 10.5M USD +8.12%
Liabilities and Equity 14.8M USD +26.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.5M USD -43.3%
Net Cash Provided by (Used in) Financing Activities 49.1K USD -92.1%
Net Cash Provided by (Used in) Investing Activities -113K USD +95.4%
Common Stock, Shares Authorized 30M shares 0%
Common Stock, Shares, Issued 11.3M shares +27%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 11.8M USD +51.5%
Deferred Tax Assets, Valuation Allowance 41M USD +3.24%
Deferred Tax Assets, Gross 41M USD +3.24%
Operating Lease, Liability 7.49M USD -36.1%
Depreciation 800K USD -63.6%
Lessee, Operating Lease, Liability, to be Paid 9.23M USD -38.4%
Property, Plant and Equipment, Gross 17.8M USD +30.9%
Operating Lease, Liability, Current 665K USD -2.76%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.29M USD -16.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.25M USD +30.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.74M USD -46.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.18M USD -35.5%
Deferred Tax Assets, Operating Loss Carryforwards 30.7M USD +4.68%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.16M USD -37.9%
Operating Lease, Payments 232K USD -26.6%
Additional Paid in Capital 466M USD +3.42%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 818K USD +42%
Share-based Payment Arrangement, Expense 497K USD +8.28%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%